Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest BVF INC/IL Stock Portfolio

$3.64Billion– No. of Holdings #62

BVF INC/IL Performance:
2024 Q1: 3.61%YTD: 3.61%2023: 5.44%

Performance for 2024 Q1 is 3.61%, and YTD is 3.61%, and 2023 is 5.44%.

About BVF INC/IL and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, BVF INC/IL reported an equity portfolio of $3.6 Billions as of 31 Mar, 2024.

The top stock holdings of BVF INC/IL are MLTX, KYMR, RVMD. The fund has invested 30% of it's portfolio in MOONLAKE IMMUNOTHERAPEUTICS and 5.7% of portfolio in KYMERA THERAPEUTICS INC.

The fund managers got completely rid off AXSOME THERAPEUTICS INC (AXSM), CENTESSA PHARMACEUTICALS PLC (CNTA) and RELAY THERAPEUTICS INC (RLAY) stocks. They significantly reduced their stock positions in LEXICON PHARMACEUTICALS INC (LXRX), CORVUS PHARMACEUTICALS INC (CRVS) and MERUS N V (MRUS). BVF INC/IL opened new stock positions in CG ONCOLOGY INC, IMMUNIC INC (IMUX) and SAB BIOTHERAPEUTICS INC (SABS). The fund showed a lot of confidence in some stocks as they added substantially to ALLAKOS INC (ALLK), UNICYCIVE THERAPEUTICS INC (UNCY) and TYRA BIOSCIENCES INC (TYRA).
BVF INC/IL Equity Portfolio Value
Last Reported on: 15 May, 2024

BVF INC/IL Annual Return Estimates Vs S&P 500

Our best estimate is that BVF INC/IL made a return of 3.61% in the last quarter. In trailing 12 months, it's portfolio return was 14.18%.

New Buys

Ticker$ Bought
cg oncology inc82,716,000
immunic inc11,751,900
sab biotherapeutics inc4,166,930

New stocks bought by BVF INC/IL

Additions to existing portfolio by BVF INC/IL

Reductions

Ticker% Reduced
lexicon pharmaceuticals inc-93.1
corvus pharmaceuticals inc-73.64
merus n v-57.41
ovid therapeutics inc-43.75
janux therapeutics inc-36.25
kura oncology inc-35.09
protagonist therapeutics inc-34.62
ideaya biosciences inc-32.78

BVF INC/IL reduced stake in above stock

Sold off

Ticker$ Sold
sab biotherapeutics inc-6,310,070
centessa pharmaceuticals plc-69,845,600
relay therapeutics inc-43,710,200
rain oncology inc-4,232,080
sutro biopharma inc-14,362,700
axsome therapeutics inc-157,676,000
silence therapeutics plc-26,201,200
iteos therapeutics inc-13,791,300

BVF INC/IL got rid off the above stocks

Sector Distribution

BVF INC/IL has about 84.1% of it's holdings in Healthcare sector.

Sector%
Healthcare84.1
Others15.9

Market Cap. Distribution

BVF INC/IL has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
MID-CAP44.9
SMALL-CAP30.5
UNALLOCATED15.9
MICRO-CAP7.3
NANO-CAP1.3

Stocks belong to which Index?

About 44.9% of the stocks held by BVF INC/IL either belong to S&P 500 or RUSSELL 2000 index.

Index%
Others55.1
RUSSELL 200044.9
Top 5 Winners (%)%
ELEV
elevation oncology inc
855.3 %
JANX
janux therapeutics inc
158.5 %
RZLT
rezolute inc
156.9 %
VIRX
viracta therapeutics inc
79.0 %
CGEM
cullinan oncology inc
67.2 %
Top 5 Winners ($)$
JANX
janux therapeutics inc
77.9 M
KYMR
kymera therapeutics inc
76.1 M
KURA
kura oncology inc
49.4 M
MRUS
merus n v
46.5 M
FDMT
4d molecular therapeutics in
46.1 M
Top 5 Losers (%)%
ANTX
an2 therapeutics inc
-83.7 %
MTEM
molecular templates inc
-38.8 %
ALLK
allakos inc
-38.8 %
RPTX
repare therapeutics inc
-35.5 %
IKNA
ikena oncology inc
-27.9 %
Top 5 Losers ($)$
MLTX
moonlake immunotherapeutics
-221.0 M
ANTX
an2 therapeutics inc
-26.8 M
RPTX
repare therapeutics inc
-26.8 M
OLMA
olema pharmaceuticals inc
-24.8 M
MIRM
mirum pharmaceuticals inc
-19.2 M

BVF INC/IL Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of BVF INC/IL

BVF INC/IL has 62 stocks in it's portfolio. About 62.3% of the portfolio is in top 10 stocks. MLTX proved to be the most loss making stock for the portfolio. JANX was the most profitable stock for BVF INC/IL last quarter.

Last Reported on: 15 May, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions